Lupin launches injectable iron formulations in India

Pharma major Lupin Limited said it launched Iron Isomaltoside injectable iron formulation under two brand names “Isofer” and “Jilazo” in India.

Lupin acquired the exclusive rights to market, distribute and sell the injectable formulation from Denmark based Pharmacosmos A/S.

The product is currently marketed in 33 countries, including 21 European Union countries under the brand name “Monofer”.

Iron Isomaltoside 1000 is indicated for the treatment of iron deficiency anemia when oral iron preparations are ineffective or cannot be used and when there is a clinical need to deliver iron rapidly. It is also used across a wide range of disease states associated with iron deficiency.

Lupin will promote Isofer and JIilazo injectable formulations through its own sales force in India.

The Hematinics market in India is currently worth around Rs 1931 cr and is growing at 11%. Out of this, the iron injectable market size is valued at Rs 310 crores with growth of 17% (IMS MAT AUG 2016).

More than 1 billion people live with iron deficiency anaemia and it is the leading cause of death for an estimated 180,000 people every year. Iron deficiency is often associated with many chronic diseases such as renal diseases including chronic kidney disease, cancers including chemotherapy induced anaemia, gynaecologic disorders including abnormal uterine bleeding and gastrointestinal diseases including inflammatory bowel disease.

Pharmacosmos A/S s a family-owned, international healthcare company headquartered in Denmark.

It is a research-based company, its ongoing R&D programme focuses on improving patients from the iron deficiency with or without anaemia.

Pharmacosmos has subsidiaries in the Nordics, the UK and the US and its products are marketed in more than 80 countries across the world.

Lupin manufactures a wide range of branded & generic formulations, biotechnology products and APIs globally.

For the financial year ended 31st March, 2016, Lupin’s Consolidated sales and Net profit stood at Rs 136,539 million ($ 2.09 billion) and Rs 22,607 million ($ 345 million) respectively.